|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价3D189在血液肿瘤患者中的安全性和免疫原性的I期临床研究
[Translation] Phase I clinical study evaluating the safety and immunogenicity of 3D189 in patients with hematological malignancies
主要目的:评价3D189在血液肿瘤患者中的安全性和免疫原性。
次要目的:初步评价3D189在血液肿瘤患者中的抗肿瘤活性。
[Translation] Primary objective: To evaluate the safety and immunogenicity of 3D189 in patients with hematological malignancies.
Secondary objective: To preliminarily evaluate the anti-tumor activity of 3D189 in patients with hematological malignancies.
100 Clinical Results associated with Xinludi Pharmaceutical (Qingdao) Co., Ltd.
0 Patents (Medical) associated with Xinludi Pharmaceutical (Qingdao) Co., Ltd.
100 Deals associated with Xinludi Pharmaceutical (Qingdao) Co., Ltd.
100 Translational Medicine associated with Xinludi Pharmaceutical (Qingdao) Co., Ltd.